Tag: multiple sclerosis

FDA Approved VUMERITY™ for Relapsing Forms of Multiple Sclerosis Treatment

Biogen Inc. and Alkermes plc announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™ (diroximel fumarate), a novel oral fumarate with a distinct chemical structure, for the treat...

Novartis’ MS Treatment Met Endpoints in Two Studies

Novartis’ ofatumumab (OMB157) has achieved the primary endpoints in two phase III trials of relapsing multiple sclerosis (MS). The data from ASCLEPIOS I and II studies has demonstrated that ofatumu...

Roche OCREVUS Study Show Reduction of Disability Progression in Multiple Sclerosis

Roche announced longer-term data from the Phase III open-label extension studies of OPERA I, OPERA II and ORATORIO showed that patients who were treated with OCREVUS® (ocrelizumab) continuously for si...

Alkermes, Biogen Announced Positive Results from Phase 3 Study of Diroximel Fumarate

biogen
Alkermes plc and Biogen Inc. announced positive topline results from EVOLVE-MS-2, a large, randomized, double-blind, five-week, Phase 3 study of diroximel fumarate, an investigational, novel oral fuma...

Janssen Announced Positive Results from the Study for Ponesimod

janssen
The Janssen Pharmaceutical Companies of Johnson & Johnson announced positive top-line results from the Phase 3 OPTIMUM study, which evaluated the efficacy and safety of ponesimod compared to Aubag...

Biogen published New Phase 3 Interim Results of EVOLVE-MS-1 Study

Biogen Inc. announced new interim data from the ongoing open-label, pivotal EVOLVE-MS-1 study indicate that the investigational treatment diroximel fumarate was generally well tolerated in people with...

EMA to Launch Safety Review of Alemtuzumab

The European Medicines Agency (EMA) has launched a safety review of alemtuzumab following reports of two deaths and several other cases of people experiencing life-threatening reactions shortly after ...

Celgene and MSAA Launched New MS Campaign

Celgene Corporation and the Multiple Sclerosis Association of America (MSAA) announced the launch of a new campaign, MS MindShift: A New View of MS, a national initiative that provides new perspective...

Novartis Presents Digital Solution for Multiple Sclerosis Patients and Physicians

novartis
Novartis today announced results from a validation study of the innovative, algorithm-based digital solution MS Progression Discussion Tool, or MSProDiscussTM. The tool aims to support and facilitate ...

Russian Scientists Develop Low-cost Method of Diagnosing Multiple Sclerosis

Researchers at the Krasnoyarsk Research Center of the Russian Academy of Sciences’ Siberian Department together with colleagues from the Institute of Basic Medical Research and Chemical Biology (Novos...

EMA Has Started a Review of The Multiple Sclerosis Medicine Lemtrada

EMA has started a review of the multiple sclerosis medicine Lemtrada (alemtuzumab) following new reports of immune-mediated conditions (caused by the body’s defence system not working properly) and pr...

FDA Approved Novartis Multiple Sclerosis Drug

Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple sclerosis, including secondary pr...

Celgene Sumitted NDA for Ozanimod

Celgene Corporation announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with relapsing forms of mult...

Celgene Submitted MAA for Ozanimod

Celgene Corporation today announced that the Company has submitted a Marketing Authorization Application to the European Medicines Agency (EMA) for ozanimod for the treatment of adults with relapsing-...

Emerald and Lonza to Develop CBD cGMP-Standard Drug for MS

Patented new chemical entity derived from synthetic cannabidiol will initially target multiple sclerosis and scleroderma. Emerald Health Pharmaceuticals and Lonza have announced an agreement for th...

FDA Approved BrainStorm Trials of MS Experimental Treatment

BrainStorm Cell Therapeutics Inc has received approval from the U.S. Food and Drug Administration to begin a clinical trial of its experimental stem cell treatment in patients with progressive multipl...